BioScrip (BIOS) vs. The Competition Financial Contrast
BioScrip (NASDAQ: BIOS) is one of 15 public companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it weigh in compared to its peers? We will compare BioScrip to related companies based on the strength of its dividends, earnings, institutional ownership, profitability, risk, analyst recommendations and valuation.
Institutional and Insider Ownership
83.6% of BioScrip shares are owned by institutional investors. Comparatively, 62.8% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by institutional investors. 0.8% of BioScrip shares are owned by insiders. Comparatively, 10.4% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of recent ratings and price targets for BioScrip and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip currently has a consensus target price of $3.75, suggesting a potential upside of 70.45%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 25.31%. Given BioScrip’s stronger consensus rating and higher probable upside, equities research analysts plainly believe BioScrip is more favorable than its peers.
Risk and Volatility
BioScrip has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, BioScrip’s peers have a beta of 1.58, meaning that their average share price is 58% more volatile than the S&P 500.
Earnings and Valuation
This table compares BioScrip and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|BioScrip||$935.59 million||-$41.50 million||-3.24|
|BioScrip Competitors||$1.06 billion||-$22.56 million||696.70|
BioScrip’s peers have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares BioScrip and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BioScrip peers beat BioScrip on 8 of the 12 factors compared.
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.